

Title page

Formatted for Psychological Medicine (original report)

The paradoxical psychological effects of LSD

Carhart-Harris RL^{1*}, Kaelen M¹, Bolstridge M¹, Williams TM³, Williams LT¹, Feilding A², Nutt DJ¹

1 Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK

2 The Beckley Foundation, Beckley Park, Oxford, UK

3 The University of Bristol, Department of Psychiatry, Bristol, UK

*r.carhart-harris@imperial.ac.uk

[Tel: 02075942679](tel:02075942679)

[Fax: 02075946548](tel:02075946548)

Acknowledgements: This research received financial and intellectual support from the Beckley Foundation and was conducted as part of a wider Beckley-Imperial research programme. The researchers would also like to thank supporters of the Wallacea.com crowd-funding campaign who played a crucial role in securing the completion of this study. The report presents independent research carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility.

Abstract (Limit = 250 words, currently 242 words)

Background: Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. This study sought to examine the acute and mid-term psychological effects of LSD in a controlled study.

Methods: Twenty healthy volunteers participated in this within-subjects study. Participants received LSD (75 μ g, i.v.) on one occasion and placebo (saline i.v.) on another, in a balanced order, with at least 2 weeks separating sessions. Acute subjective effects were measured using the Altered States of Consciousness (ASC) questionnaire and the Psychotomimetic States Inventory (PSI). A measure of optimism (the Life Orientation Test, LOT-R), the NEO PI-R personality inventory, and the Peter's Delusions Inventory (PDI) were issued at baseline and 2 weeks after each session.

Results: LSD produced robust psychological effects; including heightened mood but also high scores on the PSI, an index of psychosis-like symptoms. Increased optimism and trait openness were observed two weeks after LSD (and not placebo) and there were no changes in delusional thinking.

Conclusions: The present findings reinforce the view that psychedelics elicit psychosis-like symptoms acutely yet improve psychological wellbeing in the mid to long-term. It is proposed that acute alterations in mood are secondary to a more fundamental modulation in the regularity of cognition. Moreover, it is proposed that increased cognitive flexibility subsequent to 5-HT_{2A}R stimulation, promotes emotional lability during intoxication and leaves a residue of 'loosened cognition' in the mid to long-term that is conducive to improved psychological wellbeing.

(Main article word limit = 4500, currently 4800, without subtracting citations in body of text)

Introduction

Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or ‘psychedelic’ that alters consciousness in a marked and unusual way. The drug was first intentionally consumed by the Swiss chemist Albert Hofmann in 1943 in a self-experiment in which he ingested 250µg (a high dose) in his laboratory before travelling home. In a detailed report of his experience, written a few days later, Hofmann describes an initially unpleasant experience, characterised by altered perception, fear and paranoia: his next-door neighbour transformed into a “malevolent, insidious witch with a coloured mask”, he sensed a “disintegration of the outer world”, a “dissolution of [his] ego” and was “seized by a dreadful fear of going insane” (Hofmann, 1980).

From this account, it would be reasonable to suspect that Dr Hofmann was negatively affected by this experience but his description of his mental state the next day suggests otherwise: “I then slept, to awake the next morning with clear head... A sensation of wellbeing and renewed life flowed through me. Breakfast tasted delicious and gave me extraordinary pleasure. When I later walked out into the garden, in which the sun shone now after a spring rain, everything glistened and sparkled in a fresh light. The world was as if newly created.”(Hofmann, 1980)

When LSD was first distributed by Sandoz pharmaceuticals in 1948, product guidelines stipulated two main applications: 1) analytical psychotherapy and 2) experimental studies on psychoses. The rationale for the former was that LSD could “elicit [the] release of repressed material and provide mental relaxation for anxiety and obsessional neuroses”, and for the latter, that it could model aspects of psychosis and facilitate an understanding of its nature and pathogenesis (Hofmann, 1980). These two properties formed the basis of a large number of research projects with LSD in the 1950s and 60s. However, the apparent paradox by which the same compound can be both a model of, and yet a treatment for psychopathology, has never been properly addressed.

In the early years of research with LSD, its remarkable potency (LSD is psychoactive in doses of 25µg or lower (Hintzen and Passie, 2010)) led psychiatrists to speculate about the existence of an endogenous LSD-like ‘schizotoxin’ in the brains of patients with schizophrenia (Osmond and Smythies, 1952). In subsequent years however, focus shifted more onto therapeutic applications, such as treating alcohol dependence, mood disorders and anxiety related to dying. Human research with LSD was brought to a halt in the late 1960s due to political pressure, motivated in part by reports of adverse psychological reactions among people using the drug improperly. Ironically however, at the same time, reports of therapeutic success in the treatment of various psychiatric disorders were beginning to amount (Grinspoon and Bakalar, 1979). In the last 18 months, five new reports on clinical research with LSD have appeared in scientific press (Gasser et al., 2014, Carhart-Harris, 2014, Schmid et al., 2014, Dolder et al., 2015, Kaelen et al., 2015), one of which focused on the drug’s therapeutic effects (Gasser et al., 2014) and another, its psychotomimetic (Schmid et al., 2014).

Clinical research with psychedelics is currently undergoing a major revival and modern studies are documenting the same paradoxical properties that were historically described with LSD. For example, in a controlled study in healthy volunteers, high dose psilocybin produced strong or extreme fear in 30% of healthy volunteers and yet 80% reported improvements in wellbeing after the experience, with none reporting any decreases (Griffiths et al., 2006). Remarkably, in follow-up of the same sample, 65% reported improved wellbeing 14 months after their (single) psilocybin experience (Griffiths et al., 2008) and significant increases in the personality trait openness were also evident (MacLean et al., 2011). These finding in healthy volunteers are supplemented by an increasing number of patient studies. Clinical improvements have been observed with psilocybin-assisted psychotherapy for the treatment of tobacco (Johnson et al., 2014) and alcohol addiction (Bogenschutz et al., 2015), obsessive compulsive disorder (Moreno et al., 2006) and anxiety related to dying (Grob et al., 2011). Many of these reports mention some psychological discomfort during the acute experience; yet, the therapeutic benefits have been impressive and enduring.

Case reports of persistent psychological problems apparently precipitated by a psychedelic have considerable potential to alarm and excite concern (Reich and Hepps, 1972). However, such cases are rare and largely restricted to recreational use. Evidence does not support the view that psychedelics are harmful to mental health (Hendricks et al., 2015). Indeed, to the contrary, two recent population studies found decreased rates of suicidality and psychological distress among persons reporting previous use of psychedelics (Hendricks et al., 2015) and no evidence of any increased rates of mental health problems (Krebs and Johansen, 2013). Similarly, large meta-analyses of controlled research have found that cases of mental health complications following exposure to a psychedelic are extremely rare (i.e. < 0.1%), even in vulnerable populations (i.e. < 0.2%), and are rarer still if volunteers are properly screened (Cohen and Ditman, 1962, Studerus et al., 2011).

The main aim of the present study was to investigate the acute and ‘mid-term’ (i.e. 2 weeks after the acute experience) psychological effects of LSD in a placebo-controlled study in healthy volunteers. Validated measures of personality, optimism and psychotic symptoms were collected at baseline and two weeks post LSD/placebo and measures of mood, cognition and psychotomimetic states were collected at the end of each dosing day. It was predicted that LSD would induce emotional lability and psychosis-like symptoms acutely but increase psychological wellbeing and openness in the longer term.

Methods

Experimental design

This was a placebo-controlled, within-subjects/cross-over study, with a balanced order design. Twenty healthy volunteers were recruited to the study via word of mouth. The study received a favourable opinion from NRES committee London – West London and was conducted in accordance with Good Clinical Practice guidelines, NHS Research Governance Framework and complied with the ethical standards of the declaration of Helsinki (1975, revised 2008). Imperial College London sponsored the research and a Home Office license was obtained for research with schedule one drugs. All volunteers were sent a study information sheet and asked to read it before their screening visit.

Volunteers made three study visits: screening, dosing session one and dosing session two. Dosing sessions were separated by at least two weeks in every case and the order of receipt of LSD was balanced, i.e. half of the volunteers received LSD in dosing session one and half in dosing session two. Volunteers were blind to the dosing order but the research team were not. Dosing order was determined sequentially so that all odd numbered volunteers (i.e., S1 was the first volunteer recruited and S20 was the last) received LSD in dosing session one, whereas all even numbered volunteers received it in dosing session two. Subjective ratings were completed electronically and remotely soon after screening (baseline) and two weeks after a dosing session and sent to the researchers via email. Volunteers were instructed to complete the questionnaires in a quiet space without rushing. Two questionnaires pertaining to the acute drug experience were completed electronically within the research centre at the close of dosing days.

Screening

Prior to study enrolment, volunteers attended a screening visit at the Imperial Clinical Research Facility (ICRF) at the Hammersmith hospital in West London. The study design, procedures and psychological effects of LSD were explained and signed informed consent taken. Key exclusion criteria were: <21 years of age, personal history of diagnosed psychiatric illness, immediate family history of a psychotic disorder, an absence of previous experience with a classic psychedelic drug (e.g. LSD, mescaline, psilocybin/magic mushrooms or dimethyltryptamine/ayahuasca), pregnancy, problematic alcohol use (assessed via psychiatric interview and reported weekly units), or a medically significant condition rendering the volunteer unsuitable for the study. The decision to recruit only individuals with prior experience with psychedelics was motivated by safety considerations, i.e. to minimise the risk of an adverse response to the drug. Screening involved routine blood tests, electrocardiogram, heart rate, blood pressure, and a brief neurologic examination. All enrolled participants were deemed physically and mentally healthy by the study psychiatrist, and none had histories of drug or alcohol dependence or diagnosed psychiatric disorder. Volunteers were asked to remain abstinent from alcohol the evening before a dosing day and to refrain from using other recreational drugs for the duration of the study.

Study procedures

Participants were asked to arrive at the study centre (Cardiff University's Brain Research Imaging Centre, CUBRIC) at a specific time at or before 9:00am. A urine test for drugs of abuse and pregnancy (where relevant) was carried out. Participants were re-briefed about the procedures for the day and any recent drug and alcohol use was documented. The study physician inserted a cannula into a vein in the antecubital fossa in preparation for intravenous dosing and the volunteer was encouraged to relax prior to drug/placebo administration. The dose of LSD was 75 μ cg (p.o.) in 10ml saline. Previous research has found this dose to produce robust psychological effects that are generally well tolerated (Carhart-Harris, 2014). Placebo was 10ml saline (i.v.). Both solutions were infused over 2 minutes.

After dosing, volunteers completed a functional neuroimaging protocol. This aspect of the study will be covered in detail in a separate publication. In brief, subjects spent a period habituating to a scanner environment in a mock-magnetic resonance imaging (MRI) scanner before entering a real MRI scanner (one hour post-dosing). The MRI scanning session lasted for one hour after which a structured interview was performed and some ratings completed. Participants entered a magnetoencephalography (MEG) scanner approximately 3.5 hours post dosing. MEG scanning lasted for just over one hour. Participants were then interviewed and completed a battery of cognitive and behavioural tests (these will be detailed in a separate publication). Tasks were completed 6-7 hours post dosing.

The subjective effects of LSD were detected approximately 10 minutes post-infusion, peaked approximately 120 minutes post-infusion, and subsided to a negligible level approximately 7-8 hours post infusion. Participants were discharged by the study physician when they were considered to be functioning normally. Volunteers were either picked-up by a friend or partner, ordered a taxi, or accompanied home by the research team as far as was feasible. Volunteers were asked to contact a researcher via phone or text message once they had arrived home safely. A study psychiatrist was present for the duration of each dosing session

and one researcher was allocated to each participant to assist them throughout the day. For each participant, the same researcher was present for both dosing days.

Main outcomes and measures

Acute outcomes

Participants completed two questionnaires at the end of each study day before being discharged by the study physician. These questionnaires enquired about different aspects of the subjective experience. The first was the altered states of consciousness questionnaire (ASC); a well validated and widely used tool for defining different altered states of consciousness that has been usefully revised in recent years (Studerus et al., 2010) and the second was the psychotomimetic states inventory (PSI), a tool developed to probe the psychotomimetic effects of different drugs (Mason et al., 2008). Participants were asked to complete the questionnaires with reference to the peak subjective effects of LSD (i.e. when the effects were most intense) or with reference to how they generally felt throughout the day – e.g., if they did not notice any effects.

Mid-term outcomes

Mid-term outcomes were completed at baseline and two weeks after each dosing session. These included: the revised life orientation test (LOT-R) (Glaesmer et al., 2012), the NEO PI-R personality inventory (Costa and McCrae, 1995) and Peter's delusions inventory (PDI) (Peters et al., 1999). The LOT-R was chosen as it is a well-validated measure of trait or dispositional optimism (Scheier et al., 1994), the NEO PI-R was chosen as it is well-validated and previous research has shown its sensitivity to the enduring effects of psychedelics (MacLean et al., 2011), and the PDI was chosen as it is a well-validated measure of delusional thinking that has shown to be sensitive to psychotic-like symptoms in the general population (Peters et al., 1999).

Additional measures

Additional questionnaires completed at baseline included the Beck depression inventory (BDI) (Beck et al., 1961), the quick inventory of depressive symptoms (QIDS) (Rush et al., 2003), the state-trait anxiety inventory (STAI) (Hodges and Spielberger, 1969), the ruminative response scale (RRS) (Roelofs et al., 2006), the dysfunctional attitudes scale (DAS) (Floyd et al., 2004) and the modified version of the Tellegen Absorption Scale (MODTAS) (Tellegen and Atkinson, 1974).

Data analysis

Repeated measures ANOVAs were used to test between-condition differences in the ASC, PSI and PDI, which have multiple factors. However, since a strong prior hypothesis was held that the personality trait ‘openness’ would be significantly increased post-LSD (MacLean et al., 2011), this was analysed using a paired t-test rather than an ANOVA. The remaining four personality dimensions in the NEO PI-R were analysed using paired t-tests with Bonferroni correction for multiple comparisons. A paired t-test was used to analyse changes in the LOT-R as this has only one dimension. To test for order confounds in relation to primary outcomes, order was included as a variable in significant tests, and to further test for the influence of placebo/participation, baseline versus 2 weeks post-placebo differences in outcomes were tested for those who received placebo in their first dosing session (potential carry over effects of LSD precludes the inclusion of those who received placebo in their second dosing session). Effect sizes (Cohen’s d) were calculated for primary outcomes. For correlational analyses, Pearson product-moment coefficients were calculated and 2-tailed hypotheses tested. The problem of multiple comparisons was accounted for by Bonferroni correction.

Results

Participants


Twenty healthy volunteers participated in the study (4 females, mean age = 30.9 ± 7.8 , range = 22-47). All had at least one previous experience with a classic psychedelic drug (mean estimated LSD uses = 14 ± 17.8 , range = 0-70) but not within 14 days of the first dosing

session (mean last use of LSD = 899.3 ± 1363 , range = 14-5400 days). Self-estimates of other drug-use were as follows (mean, SD, range): weekly alcohol units = 10.3 ± 9 ; daily cigarettes = 0.3 ± 1.1 , 0-5; cannabis uses = 705 ± 639 , 30-2000; MDMA uses = 27 ± 24 , 2-100; psilocybin/magic mushroom uses = 9.4 ± 7.8 , 1-35; ketamine uses = 3.6 ± 5 , 0-20; cocaine uses = 9.6 ± 9.4 , 0-30. Other baseline scores were as follows: BDI = 0.6 ± 0.9 , 0-3; QIDS = 4.2 ± 3.1 , 0-10; DAS = 105.5 ± 23 , 55-146; RRS = 35.4 ± 7.9 , 24-52; STAI = 29.2 ± 4.6 , 20-38; MODTAS = 58.3 ± 19.8 , 19-89.

Acute subjective effects of LSD

A repeated measures ANOVA revealed a significant main effect of drug ($F[1,19] = 82.6$, $p < 0.001$) and a significant drug x ASC interaction ($F[10,190] = 10.3$, $p < 0.001$). Post-hoc t-tests revealed that all 11 dimensions or factors of the ASC were rated significantly higher after LSD than placebo ($p < 0.01$). Mean scores for each factor are displayed in the radar chart in figure 1. It is notable that although the LSD experience was dominated by changes in visual perception (i.e. elementary imagery, complex imagery and audio-visual synesthesia), the factor ‘blissful state’ was markedly elevated under the drug ($+0.37 \pm 0.28$, Cohen’s $d = 1.65$). Although still significantly increased, the factor ‘anxiety’ was the least elevated under LSD ($+0.15 \pm 0.2$, Cohen’s $d = 1.03$). These results indicate a marked increase in emotional arousal and lability under LSD but with a distinct bias towards positive affect. Reinforcing this, a t-test revealed that increases in ‘blissful state’ under LSD were significantly greater than increases in ‘anxiety’ ($t = -3.7$, $df = 19$, $p < 0.01$, Cohen’s $d = 0.91$).


Altered states of consciousness (ASC) questionnaire



Insert figure 1 here (ASC chart)

Figure 1. Acute effects of LSD measured via the ASC: Displayed are the mean scores on each of the 11 dimensions of the ASC for the LSD (black) and placebo (gray) conditions.

A repeated measures ANOVA revealed a significant main effect of condition on the PSI ($F[1,19] = 65.19, p < 0.001$) and a significant condition \times PSI interaction ($F[5,95] = 35.2, p < 0.001$). Mean scores for each factor of the PSI are shown in the bar chart in figure 2. Post-hoc t-tests revealed that all factors, except for 'anhedonia', were significantly increased under the drug ($p < 0.01$). The most marked effect was on 'cognitive disorganisation' (Cohen's $d = 2.37$) which is related to thought-disorder in psychosis, but other highly characteristic aspects of psychosis such as 'delusional thinking' (Cohen's $d = 1.63$) and 'paranoia' (Cohen's $d = 0.83$) were also markedly increased under the drug.




Insert figure 2 here (PSI chart)

Figure 2. Acute effects measured of LSD measured via the PSI. Displayed are the mean scores plus the positive standard errors from the mean (SEM) for each of the 6 factors of the PSI, plus the total score (which is a sum of the scores of the 6 factors). All factors, except for anhedonia were scored significantly higher under LSD than placebo.

Mid-term subjective effects of LSD

Optimism was significantly increased two weeks after LSD ($t = 2.91$, $df = 18$, $p = 0.005$, Cohen's $d = 0.56$), as was trait openness ($t = 1.95$, $df = 19$, $p = 0.03$, Cohen's $d = 0.16$) (figure 3), and there were no such changes in optimism or personality post-placebo. In exploratory t-tests, there was a trend towards an increase in trait agreeableness post-LSD ($t = 2.2$, $df = 19$, $p = 0.038$, Cohen's $d = 0.21$); however, this did not survive correction for multiple comparisons (corrected $p = (0.038 \times 4) = 0.15$).



Insert figure 3 here (combined bar charts)

Figure 3. Mid-term effects of LSD: These charts display paired data-points for optimism (chart on the left) and openness (chart on the right) scores at baseline and 2 weeks after LSD for each participant. Also displayed on each chart are the mean scores (horizontal bars) and the positive SEM. Both optimism and openness were significantly increased after LSD. There was no effect of order of receipt of LSD nor were there any changes in optimism or personality 2 weeks after receipt of placebo.

Repeated measures ANOVA found no change in delusional thinking (PDI scores) 2 weeks after LSD ($p > 0.05$). In fact, exploratory t-tests suggested a trend towards less distress ($t = 1.92$, $df = 19$, $p = 0.068$) and preoccupation with ‘delusional thoughts’ ($t = 1.92$, $df = 19$, $p = 0.07$) but these trends were not significant, even before correction for multiple comparisons. There were no changes in PDI scores post placebo.

Predictors of the mid-term effects of LSD

Regarding *baseline* predictors of the mid-term effects of LSD, focus was placed on personality (as measured by the NEO PI-R), depression (measured by the QIDS) and anxiety (measured by the STAI). A negative correlation was found between baseline agreeableness and increases in optimism post-LSD ($r = -0.56$, $r^2 = 0.31$, $p = 0.014$) and positive correlations were found between baseline depression ($r = 0.53$, $r^2 = 0.28$, $p = 0.024$) and anxiety ($r = 0.49$, $r^2 = 0.24$, $p = 0.04$) and the post-LSD increases in openness. However, none of these survived correction for multiple comparisons (revised $p = 0.05/7 = 0.007$).

Regarding *acute* predictors of the mid-term effects to LSD, there was a negative correlation between acute anxiety (ASC) and post-LSD increases in optimism ($r = -0.47$, $r^2 = 0.22$, $n = 19$, $p = 0.04$) and positive correlations between impaired/disorganised cognition scores on the ASC and PSI and post-LSD increases in openness (ASC: $r = 0.44$, $r^2 = 0.2$, $n = 20$, $p = 0.049$; PSI: $r = 0.52$, $r^2 = 0.26$, $n = 20$, $p = 0.019$) but these correlations also failed to survive correction for multiple comparisons (revised $p = 0.5/17 = 0.003$).

Discussion

The primary aim of this study was to investigate the acute and mid-term subjective effects of LSD in a controlled study in order to advance our understanding of its psychological effects. It was hypothesised that LSD would increase emotional lability and psychosis-like symptoms acutely, and increase optimism and openness two weeks later, and these hypotheses were supported by the data.

Focusing first on LSD's acute effects, scores on the PSI reinforce the view that LSD is a potent psychotomimetic. Previous studies have examined PSI scores after sleep deprivation (Petrovsky et al., 2014), dreaming (Mason and Wakerley, 2012), cannabis (Mason et al., 2008), THC (Stokes et al., 2009) and ketamine intoxication (Mason et al., 2008). Although both dreaming and sleep deprivation elevated subscales of the PSI, only the aforementioned drugs produced appreciable psychosis-like symptoms – and still not to the same extent as LSD in the present study. For example, mean total scores on the PSI were 24 ± 10.9 post-ketamine infusion (150mg/ml plasma), 15.9 ± 11 post-THC (10mg p.o.) and 33.3 ± 19.5 post-cannabis-use (smoked, quantity unknown), whereas the mean total PSI score in the present study was 45.8 ± 21 . To our knowledge, only cannabis in highly schizotypal individuals (Mason et al., 2009) has produced PSI scores of an equivalent magnitude to those seen here with LSD.

More generally, relatively strong subjective effects were produced by the present dose of LSD (i.e. 75 μ g, i.v.) as indexed by the ASC. In previous studies, psilocybin (115-350 μ g/kg PO), MDMA (1.5-1.7mg/kg PO), and ketamine (6-12 μ g/kg per min i.v.), produced effects of a lower magnitude than those seen here (Studerus et al., 2010) but in a recent study with 200 μ g LSD (p.o.), ASC scores were of a similar magnitude to those observed here (Schmid et al., 2014).

With the PSI results in mind, it is worth briefly discussing the relative merits of different drug models of psychosis. Ketamine is often described as an especially meritorious model of psychosis because it can induce both positive and negative symptoms (Krystal et al., 1994). However, the premise that negative symptoms can be modelled by an acute drug state is questionable (Carhart-Harris et al., 2013). For example, it has been argued that negative symptoms are non-specific for psychosis (i.e. they are also prevalent in depression (Kaiser et al., 2011, Carhart-Harris et al., 2013). Positive symptoms *are* specific for psychosis however but comparison studies have suggested that these are better modelled by classic psychedelics than ketamine (Carhart-Harris et al., 2013, Gouzoulis-Mayfrank et al., 2005). Others have shown that THC is a particularly potent inducer of positive psychotic symptoms (Morrison et al., 2009). Thus, future studies might compare the psychotomimetic properties of THC, ketamine and a classic psychedelic in a controlled, cross-over design to systematically assess the relative value of these different models.

Based on the PSI results, one might infer that participants' acute LSD experiences were dominated by unpleasant psychosis-like phenomena; however, this was not the case. Some volunteers did show frank psychotic phenomena during their LSD experiences (e.g. paranoid and delusional thinking) but at the group level, positive mood was more common. For example, scores on the (positively valenced) 'blissful experience' dimension of the ASC were significantly higher than scores on the (negatively valenced) 'anxiety' dimension. Consistent with the view that LSD is more likely to produce positive than negative mood, a separate study with LSD (200 μ g, p.o.) reported marked positive mood effects, described as 'MDMA-like' (Schmid et al., 2014); an important caveat however, is that both the Schmid et al. study

and the present one, recruited volunteers with previous experience with psychedelics. Thus, positive prior experiences and positive regard towards LSD may have biased outcomes.

The findings that optimism and openness are increased 2 weeks after LSD are consistent with previous findings (MacLean et al., 2011, Griffiths et al., 2006, Griffiths et al., 2008), suggesting that improved psychological wellbeing and increased openness are relatively reliable mid to long-term effects of psychedelics. That there were no increases in psychotic symptomatology at the 2 week end point is also consistent with reports of preserved or even improved mental health among populations of people that have used psychedelic drugs (Krebs and Johansen, 2013, Hendricks et al., 2015, Bouso et al., 2012). These results are also consistent with previous findings that psychedelics can be useful in treating certain psychiatric disorders (Grob et al., 2011, Gasser et al., 2014, Johnson et al., 2014, Bogenschutz et al., 2015, Moreno et al., 2006) as well as the notion that they may have therapeutic potential in the treatment of mood disorders such as depression (Carhart-Harris et al., 2014b). High dispositional optimism is associated with a range of positive health and socioeconomic outcomes (Carver and Scheier, 2014); thus, the increases in optimism observed here may be treated as further evidence of the therapeutic potential of psychedelic drugs.

A limitation of the present study was the relatively short duration of the follow-up period (i.e. 2 weeks); however, longer-term follow-up is planned and two weeks is still relevant when considering potential therapeutic applications (Zarate et al., 2006). Another limitation is the single-blind design; however, the classic double-blind model can feel contrived in the context of controlled studies with potent psychoactive compounds such as LSD, since the blind is almost universally ineffective. A single-blind design allowed us to introduce some uncertainty however, and so was considered better than an entirely open-label design. The inclusion of an ‘active placebo’ condition might be one way to address the ineffectiveness of the blind in studies with psychedelics; however, an inert placebo was required in the present study in order to provide a valid baseline for the neuroimaging contrasts. Related to this, a final limitation to mention is that the LSD and placebo sessions involved MRI and MEG scans that each lasted for over 60 minutes. Despite careful screening, preparation and some

prior exposure to MRI and/or MEG, brain imaging environments can be particularly demanding for some individuals, particularly under psychedelics (Studerus et al., 2011), and this may have contributed to the pronounced PSI scores observed here with LSD. Individuals are known to be especially sensitive to the environment in which they experience the effects of a psychedelic (Johnson et al., 2008), and so this factor should be considered when evaluating the present study's findings.

With these caveats entered, it is important to attempt an explanation of how LSD can be both acutely psychotomimetic and yet psychologically beneficial in the mid to long-term, and insights from neurobiology may be helpful in this regard. There is a consensus that serotonin 2A receptor (5-HT_{2A}R) agonism is central to the psychopharmacology of psychedelics, e.g. affinity for the 5-HT_{2A}R correlates strongly with their potencies (Glennon et al., 1984), and pre-treatment with a 5-HT_{2A}R antagonist effectively abolishes the classic 'psychedelic' effects of psilocybin (Vollenweider et al., 1998). The principal psychological purpose or function of the 5-HT_{2A}R is poorly understood; however, it is known that 5-HT_{2A}R stimulation promotes certain aspects of learning (Romano et al., 2010, Harvey et al., 2004, Harvey, 2003) and cognition (Williams et al., 2002, King et al., 1972). Specifically, 5-HT_{2A}R stimulation enhances the *flexibility* of cognition (Boulougouris et al., 2008), which may be related to reports of enhanced imagination (Carhart-Harris, 2014) and creative thinking (Frecska et al., 2012) with psychedelics. Interestingly, an association has been found between positive mood and flexible, creative thinking (Hirt et al., 2008, Lin et al., 2014) and this may explain why both are associated with psychedelics. Indeed, the positive mood effects of psilocybin (a direct 5-HT_{2A}R agonist) and MDMA (a potent serotonin 'releaser') are significantly attenuated by pre-treatment with the 5-HT_{2A}R antagonist ketanserin (van Wel et al., 2012, Kometer et al., 2012).

Psychedelics also transiently impair certain aspects of cognition however, such as the ability to focus and concentrate (Umbricht et al., 2003, Vollenweider et al., 2007), which is consistent with the high ratings of impaired cognition in the present study (figure 1 & 2). It is also important to acknowledge that while 5-HT_{2A}R antagonism attenuates the positive mood effects of psilocybin (and MDMA), it also attenuates positive psychotic symptoms that can be

produced by the drug (Carter et al., 2007) and 5-HT_{2A}R agonism has been linked with anxiety related behaviours in rodents (Weisstaub et al., 2006).

Thus, 5-HT_{2A}R stimulation has been associated with both positive and negative facets of the acute psychedelic state (i.e. positive mood but also anxiety and psychotic symptoms), so how can we reconcile these things with each other? Is there a more fundamental action of psychedelics that can explain both effects? As reported above, 5-HT_{2A}R stimulation has been associated with enhanced cognitive flexibility; inspired by recent neuroimaging findings (Roseman et al., 2014, Tagliazucchi et al., 2014, Muthukumaraswamy et al., 2013, Carhart-Harris et al., 2012, Petri et al., 2014), the psychedelic state has been characterised as an ‘entropic’ state in which the mind/brain operates outside of its normal, optimal level of order, in a realm of relative disorder (Carhart-Harris et al., 2014b). It may be that what underlies both facets of the psychedelic state and can resolve the ‘valence paradox’ therefore, is this principle of increased cognitive entropy (see figure 4). Accordingly, we predict that disordered or entropic cognition is a *more fundamental* characteristic of the psychedelic state than either positive or negative mood. This is something that could be tested by carrying out a principal components analysis of the ASC data; we would predict that valence non-specific items and particularly those related to ‘entropic cognition’ (such as loss of self/ego, loss of ego-boundaries, altered meaning and muddled thinking) would load more heavily onto the first principal component than valence specific items (such as feeling euphoric or sad). Acute entropic processes may also be useful predictors of the mid/long-terms effects of psychedelics, and the (trend-level) relationship between impaired/disordered cognition and subsequent increases in trait openness might be suggestive of such an association.




Figure 4 here (schematic)

Figure 4. The action of psychedelics on the mind and brain: This empirically informed model illustrates the hypothesised relationship between three different neurobiological or physiological states and their psychological counterparts. Specifically, it is predicted that deficient 5-HT₂AR stimulation has a stultifying influence on cognition, promoting pessimism, neuroticism and rigid thinking (phase 1). Informed by neuroimaging studies with psychedelics (Carhart-Harris et al., 2014a), 5-HT₂AR stimulation is associated with unconstrained brain network dynamics and the characteristic 'entropic' quality of cognition in the psychedelic state (phase 2). Finally, it is hypothesised that an acute 'onslaught' or 'blast' of 5-HT₂AR stimulation, via the action of a psychedelic, has a residual influence on brain network dynamics and associated cognition (phase 3). 5-HT₂AR stimulation is described as having a 'loosening' or 'lubricating' influence on cognition and this is hypothesised to be conducive to improved psychological wellbeing. *The long-term effects of psychedelics on brain network dynamics have yet to be formally investigated.

Before concluding, it is worth considering one final important matter. The discussion so far has focused mainly on the paradoxical *acute* psychological effects of psychedelics. However, as the present results have demonstrated, the acute effects of psychedelics can be quite different to their longer-term effects, and it is arguably the latter that are more clinically relevant. Previous studies have shown that trait characteristics, such as personality and outlook, can be significantly altered by psychedelics (MacLean et al., 2011, Griffiths et al., 2008). Moreover, associations have been found between certain psychological traits and the 5-HT_{2AR} (Frokjaer et al., 2008, Meyer et al., 2003, Ott et al., 2005, Turecki et al., 1999, Bhagwagar et al., 2006). Specifically, deficient 5-HT_{2AR} stimulation has been linked with depression-related behaviours such as suicide (Turecki et al., 1999), dysfunctional or excessively pessimistic attitudes (Bhagwagar et al., 2006, Meyer et al., 2003) and neuroticism (Frokjaer et al., 2008). In this context, increased psychological wellbeing (Griffiths et al., 2008), openness (MacLean et al., 2011), decreased suicidality (Hendricks et al., 2015) and now increased optimism after a ‘blast’ of 5-HT_{2AR} stimulation may begin to make sense. We predict that deficient 5-HT_{2AR} stimulation causes cognition to ‘stultify’, whereas 5-HT_{2AR} stimulation loosens cognition and associated brain dynamics, serving as a metaphorical ‘lubricant’ for the mind and brain. We predict that this loosening effect persists beyond the acute intoxication phase and can potentially explain the mid to long-term psychological effects of psychedelics. Recent reports of enduring brain changes with 5-HT_{2AR} stimulation and psychedelic drug-use (Bouso et al., 2015), as well as speculations on the function of serotonin in the brain (Branchi, 2011), may herald the beginnings of an understanding of this important matter. We intend to detail the acute brain effects of LSD in forthcoming neuroimaging papers and to investigate the long-term psychological and brain effects of psychedelics in future studies.

In conclusion, this study sought to investigate the paradoxical psychological effects of LSD in a controlled study in healthy volunteers. LSD produced robust acute psychological effects that were characterised by psychosis-like symptoms but also positive mood. Mid-term effects included significant increases in optimism and the personality trait openness and no increases in delusional thinking. A mechanistic explanation for these findings was proposed based on the ‘entropic brain’ hypothesis (Carhart-Harris et al., 2014a).

References

BECK, A. T., WARD, C. H., MENDELSON, M., MOCK, J. & ERBAUGH, J. 1961. An inventory for measuring depression. *Arch Gen Psychiatry*, 4, 561-71.

BHAGWAGAR, Z., HINZ, R., TAYLOR, M., FANCY, S., COWEN, P. & GRASBY, P. 2006. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. *Am J Psychiatry*, 163, 1580-7.

BOGENSCHUTZ, M. P., FORCEHIMES, A. A., POMMY, J. A., WILCOX, C. E., BARBOSA, P. & STRASSMAN, R. J. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. *J Psychopharmacol*.

BOULOGOURIS, V., GLENNON, J. C. & ROBBINS, T. W. 2008. Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. *Neuropsychopharmacology*, 33, 2007-19.

BOUSO, J. C., GONZALEZ, D., FONDEVILA, S., CUTCHET, M., FERNANDEZ, X., RIBEIRO BARBOSA, P. C., ALCAZAR-CORCOLES, M. A., ARAUJO, W. S., BARBANOJ, M. J., FABREGAS, J. M. & RIBA, J. 2012. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. *PLoS One*, 7, e42421.

BOUSO, J. C., PALHANO-FONTES, F., RODRIGUEZ-FORNELLS, A., RIBEIRO, S., SANCHES, R., CRIPPA, J. A., HALLAK, J. E., DE ARAUJO, D. B. & RIBA, J. 2015. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. *Eur Neuropsychopharmacol*.

BRANCHI, I. 2011. The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. *Psychoneuroendocrinology*, 36, 339-51.

CARHART-HARRIS, R., BRUGGER, S., NUTT, D. & STONE, J. 2013. Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. *J Psychopharmacol*, 27, 771-8.

CARHART-HARRIS, R., KAELEN, M., WHALLEY, M., BOLSTRIDGE, M., FEILDING, A., NUTT, D. 2014. LSD enhances suggestibility in healthy volunteers. *Psychopharmacology (Berl)*.

CARHART-HARRIS, R. L., ERRITZOE, D., WILLIAMS, T., STONE, J. M., REED, L. J., COLASANTI, A., TYACKE, R. J., LEECH, R., MALIZIA, A. L., MURPHY, K., HOBDEN, P., EVANS, J., FEILDING, A., WISE, R. G. & NUTT, D. J. 2012. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proc Natl Acad Sci U S A*, 109, 2138-43.

CARHART-HARRIS, R. L., LEECH, R., HELLYER, P. J., SHANAHAN, M., FEILDING, A., TAGLIAZUCCHI, E., CHIALVO, D. R. & NUTT, D. 2014a. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. *Front Hum Neurosci*, 8, 20.

CARHART-HARRIS, R. L., LEECH, R., TAGLIAZUCCHI, E., HELLYER, P. J., CHIALVO, D. R., FEILDING, A. & NUTT, D. 2014b. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. *Frontiers in Human Neuroscience*, 8, 20.

CARTER, O. L., HASLER, F., PETTIGREW, J. D., WALLIS, G. M., LIU, G. B. & VOLLENWEIDER, F. X. 2007. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. *Psychopharmacology (Berl)*, 195, 415-24.

CARVER, C. S. & SCHEIER, M. F. 2014. Dispositional optimism. *Trends Cogn Sci*, 18, 293-9.

COHEN, S. & DITMAN, K. S. 1962. Complications associated with lysergic acid diethylamide (LSD-25). *JAMA*, 181, 161-2.

COSTA, P. T., JR. & MCCRAE, R. R. 1995. Domains and facets: hierarchical personality assessment using the revised NEO personality inventory. *J Pers Assess*, 64, 21-50.

DOLDER, P. C., SCHMID, Y., HASCHKE, M., RENTSCH, K. M. & LIECHTI, M. E. 2015. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. *Int J Neuropsychopharmacol*.

FLOYD, M., SCOGIN, F. & CHAPLIN, W. F. 2004. The Dysfunctional Attitudes Scale: factor structure, reliability, and validity with older adults. *Aging Ment Health*, 8, 153-60.

FRECSKA, E., MORE, C. E., VARGHA, A. & LUNA, L. E. 2012. Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. *J Psychoactive Drugs*, 44, 191-9.

FROKJAER, V. G., MORTENSEN, E. L., NIELSEN, F. A., HAUGBOL, S., PINBORG, L. H., ADAMS, K. H., SVARER, C., HASSELBALCH, S. G., HOLM, S., PAULSON, O. B. & KNUDSEN, G. M. 2008. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. *Biol Psychiatry*, 63, 569-76.

GASSER, P., HOLSTEIN, D., MICHEL, Y., DOBLIN, R., YAZAR-KLOSINSKI, B., PASSIE, T. & BRENNNEISEN, R. 2014. Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. *J Nerv Ment Dis*.

GLAESMER, H., RIEF, W., MARTIN, A., MEWES, R., BRAHLER, E., ZENGER, M. & HINZ, A. 2012. Psychometric properties and population-based norms of the Life Orientation Test Revised (LOT-R). *Br J Health Psychol*, 17, 432-45.

GLENNON, R. A., TITELER, M. & MCKENNEY, J. D. 1984. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. *Life Sci*, 35, 2505-11.

GOUZOULIS-MAYFRANK, E., HEEKEREN, K., NEUKIRCH, A., STOLL, M., STOCK, C., OBRADOVIC, M. & KOVAR, K. A. 2005. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. *Pharmacopsychiatry*, 38, 301-11.

GRIFFITHS, R., RICHARDS, W., JOHNSON, M., MCCANN, U. & JESSE, R. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J Psychopharmacol*, 22, 621-32.

GRIFFITHS, R. R., RICHARDS, W. A., MCCANN, U. & JESSE, R. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology (Berl)*, 187, 268-83; discussion 284-92.

GRINSPOON, L. & BAKALAR, J. B. 1979. *Psychedelic drugs reconsidered*, New York, Basic Books.

GROB, C. S., DANFORTH, A. L., CHOPRA, G. S., HAGERTY, M., MCKAY, C. R., HALBERSTADT, A. L. & GREER, G. R. 2011. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*, 68, 71-8.

HARVEY, J. A. 2003. Role of the serotonin 5-HT(2A) receptor in learning. *Learn Mem*, 10, 355-62.

HARVEY, J. A., QUINN, J. L., LIU, R., ALOYO, V. J. & ROMANO, A. G. 2004. Selective remodeling of rabbit frontal cortex: relationship between 5-HT2A receptor density and associative learning. *Psychopharmacology (Berl)*, 172, 435-42.

HENDRICKS, P. S., THORNE, C. B., CLARK, C. B., COOMBS, D. W. & JOHNSON, M. W. 2015. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *J Psychopharmacol*.

HINTZEN, A. & PASSIE, T. 2010. *The pharmacology of LSD: a critical review*, Oxford, Oxford University Press.

HIRT, E. R., DEVERS, E. E. & MCCREA, S. M. 2008. I want to be creative: exploring the role of hedonic contingency theory in the positive mood-cognitive flexibility link. *J Pers Soc Psychol*, 94, 214-30.

HODGUES, W. F. & SPIELBERGER, C. D. 1969. An indicant of trait or state anxiety? *J Consult Clin Psychol*, 33, 430-4.

HOFMANN, A. 1980. *LSD : my problem child*, N.Y., McGraw-Hill.

JOHNSON, M., RICHARDS, W. & GRIFFITHS, R. 2008. Human hallucinogen research: guidelines for safety. *J Psychopharmacol*, 22, 603-20.

JOHNSON, M. W., GARCIA-ROMEU, A., COSIMANO, M. P. & GRIFFITHS, R. R. 2014. Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol*, 28, 983-92.

KAELEN, M., BARRETT, F. S., ROSEMAN, L., LORENZ, R., FAMILY, N., BOLSTRIDGE, M., CURRAN, H. V., FEILDING, A., NUTT, D. J. & CARHART-HARRIS, R. L. 2015. LSD enhances the emotional response to music. *Psychopharmacology (Berl)*, 232, 3607-14.

KAISER, S., HEEKEREN, K. & SIMON, J. J. 2011. The negative symptoms of schizophrenia: category or continuum? *Psychopathology*, 44, 345-53.

KING, A. R., MARTIN, I. L. & SEYMOUR, K. A. 1972. Reversal learning facilitated by a single injection of lysergic acid diethylamide (LSD 25) in the rat. *Br J Pharmacol*, 45, 161P-162P.

KOMETER, M., SCHMIDT, A., BACHMANN, R., STUDERUS, E., SEIFRITZ, E. & VOLLENWEIDER, F. X. 2012. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. *Biol Psychiatry*, 72, 898-906.

KREBS, T. S. & JOHANSEN, P. O. 2013. Psychedelics and mental health: a population study. *PLoS One*, 8, e63972.

KRYSTAL, J. H., KARPER, L. P., SEIBYL, J. P., FREEMAN, G. K., DELANEY, R., BREMNER, J. D., HENINGER, G. R., BOWERS, M. B., JR. & CHARNEY, D. S. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry*, 51, 199-214.

LIN, W. L., TSAI, P. H., LIN, H. Y. & CHEN, H. C. 2014. How does emotion influence different creative performances? The mediating role of cognitive flexibility. *Cogn Emot*, 28, 834-44.

MACLEAN, K. A., JOHNSON, M. W. & GRIFFITHS, R. R. 2011. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol*, 25, 1453-61.

MASON, O., MORGAN, C. J., DHIMAN, S. K., PATEL, A., PARTI, N. & CURRAN, H. V. 2009. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. *Psychol Med*, 39, 951-6.

MASON, O. & WAKERLEY, D. 2012. The psychotomimetic nature of dreams: an experimental study. *Schizophr Res Treatment*, 2012, 872307.

MASON, O. J., MORGAN, C. J., STEFANOVIC, A. & CURRAN, H. V. 2008. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. *Schizophr Res*, 103, 138-42.

MEYER, J. H., MCMAIN, S., KENNEDY, S. H., KORMAN, L., BROWN, G. M., DASILVA, J. N., WILSON, A. A., BLAK, T., EYNAN-HARVEY, R., GOULDING, V. S., HOULE, S. & LINKS, P. 2003. Dysfunctional attitudes and 5-HT₂ receptors during depression and self-harm. *American Journal of Psychiatry*, 160, 90-9.

MORENO, F. A., WIEGAND, C. B., TAITANO, E. K. & DELGADO, P. L. 2006. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *J Clin Psychiatry*, 67, 1735-40.

MORRISON, P. D., ZOIS, V., MCKEOWN, D. A., LEE, T. D., HOLT, D. W., POWELL, J. F., KAPUR, S. & MURRAY, R. M. 2009. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. *Psychol Med*, 39, 1607-16.

MUTHUKUMARASWAMY, S. D., CARHART-HARRIS, R. L., MORAN, R. J., BROOKES, M. J., WILLIAMS, T. M., ERRIZOE, D., SESSA, B., PAPADOPoulos, A., BOLSTRIDGE, M., SINGH, K. D., FEILDING, A., FRISTON, K. J. & NUTT, D. J. 2013. Broadband Cortical Desynchronization Underlies the Human Psychedelic State. *J Neurosci*, 33, 15171-15183.

OSMOND, H. & SMYTHIES, J. 1952. Schizophrenia: a new approach. *J Ment Sci*, 98, 309-15.

OTT, U., REUTER, M., HENNIG, J. & VAITL, D. 2005. Evidence for a common biological basis of the Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms. *Am J Med Genet B Neuropsychiatr Genet*, 137B, 29-32.

PETERS, E. R., JOSEPH, S. A. & GARETY, P. A. 1999. Measurement of delusional ideation in the normal population: introducing the PDI (Peters et al. Delusions Inventory). *Schizophr Bull*, 25, 553-76.

PETRI, G., EXPERT, P., TURKHEIMER, F., CARHART-HARRIS, R., NUTT, D., HELLYER, P. J. & VACCARINO, F. 2014. Homological scaffolds of brain functional networks. *J R Soc Interface*, 11, 20140873.

PETROVSKY, N., ETTINGER, U., HILL, A., FRENZEL, L., MEYHOFER, I., WAGNER, M., BACKHAUS, J. & KUMARI, V. 2014. Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. *J Neurosci*, 34, 9134-40.

REICH, P. & HEPPS, R. B. 1972. Homicide during a psychosis induced by LSD. *JAMA*, 219, 869-71.

ROELOFS, J., MURIS, P., HUIBERS, M., PEETERS, F. & ARNTZ, A. 2006. On the measurement of rumination: a psychometric evaluation of the ruminative response scale and the rumination on sadness scale in undergraduates. *J Behav Ther Exp Psychiatry*, 37, 299-313.

ROMANO, A. G., QUINN, J. L., LI, L., DAVE, K. D., SCHINDLER, E. A., ALOYO, V. J. & HARVEY, J. A. 2010. Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al. *Psychopharmacology (Berl)*, 212, 441-8.

ROSEMAN, L., LEECH, R., NUTT, D. J., FEILDING, A. & CARHART-HARRIS, R. L. 2014. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. *Frontiers in Human Neuroscience*, 8.

RUSH, A. J., TRIVEDI, M. H., IBRAHIM, H. M., CARMODY, T. J., ARNOW, B., KLEIN, D. N., MARKOWITZ, J. C., NINAN, P. T., KORNSTEIN, S., MANBER, R., THASE, M. E., KOCSIS, J. H. & KELLER, M. B. 2003. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry*, 54, 573-83.

SCHEIER, M. F., CARVER, C. S. & BRIDGES, M. W. 1994. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. *J Pers Soc Psychol*, 67, 1063-78.

SCHMID, Y., ENZLER, F., GASSEN, P., GROUZMANN, E., PRELLER, K. H., VOLLENWEIDER, F. X., BRENNISEN, R., MULLER, F., BORGWARDT, S. & LIECHTI, M. E. 2014. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. *Biol Psychiatry*.

STOKES, P. R., MEHTA, M. A., CURRAN, H. V., BREEN, G. & GRASBY, P. M. 2009. Can recreational doses of THC produce significant dopamine release in the human striatum? *Neuroimage*, 48, 186-90.

STUDERUS, E., GAMMA, A. & VOLLENWEIDER, F. X. 2010. Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS One*, 5, e12412.

STUDERUS, E., KOMETER, M., HASLER, F. & VOLLENWEIDER, F. X. 2011. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. *J Psychopharmacol*, 25, 1434-52.

TAGLIAZUCCHI, E., CARHART-HARRIS, R., LEECH, R., NUTT, D. & CHIALVO, D. R. 2014. Enhanced repertoire of brain dynamical states during the psychedelic experience. *arXiv preprint arXiv:1405.6466*.

TELLEGGEN, A. & ATKINSON, G. 1974. Openness to absorbing and self-altering experiences ("absorption"), a trait related to hypnotic susceptibility. *J Abnorm Psychol*, 83, 268-77.

TURECKI, G., BRIERE, R., DEWAR, K., ANTONETTI, T., LESAGE, A. D., SEGUIN, M., CHAWKY, N., VANIER, C., ALDA, M., JOOBER, R., BENKELFAT, C. & ROULEAU, G. A. 1999. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. *Am J Psychiatry*, 156, 1456-8.

UMBRECHT, D., VOLLENWEIDER, F. X., SCHMID, L., GRUBEL, C., SKRABO, A., HUBER, T. & KOLLER, R. 2003. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. *Neuropsychopharmacology*, 28, 170-81.

VAN WEL, J. H., KUYPERS, K. P., THEUNISSEN, E. L., BOSKER, W. M., BAKKER, K. & RAMAEKERS, J. G. 2012. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. *PLoS One*, 7, e40187.

VOLLENWEIDER, F. X., CSOMOR, P. A., KNAPPE, B., GEYER, M. A. & QUEDNOW, B. B. 2007. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. *Neuropsychopharmacology*, 32, 1876-87.

VOLLENWEIDER, F. X., VOLLENWEIDER-SCHERPENHUYZEN, M. F., BABLER, A., VOGEL, H. & HELL, D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2agonist action. *Neuroreport*, 9, 3897-902.

WEISSTAUB, N. V., ZHOU, M., LIRA, A., LAMBE, E., GONZALEZ-MAESO, J., HORNUNG, J. P., SIBILLE, E., UNDERWOOD, M., ITOHARA, S., DAUER, W. T., ANSORGE, M. S., MORELLI, E., MANN, J. J., TOTH, M., AGHAJANIAN, G., SEALFON, S. C., HEN, R. & GINGRICH, J. A. 2006. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. *Science*, 313, 536-40.

WILLIAMS, G. V., RAO, S. G. & GOLDMAN-RAKIC, P. S. 2002. The physiological role of 5-HT2A receptors in working memory. *J Neurosci*, 22, 2843-54.

ZARATE, C. A., JR., SINGH, J. B., CARLSON, P. J., BRUTSCHE, N. E., AMELI, R., LUCKENBAUGH, D. A., CHARNEY, D. S. & MANJI, H. K. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry*, 63, 856-64.